NCT02488330 - An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 27, 2015

Primary Completion Date

June 29, 2018

Study Completion Date

June 29, 2018

Conditions

Solid Tumor

Interventions

DRUG

Onartuzumab

Onartuzumab 10 mg/kg or 15 mg/kg will be administered intravenously on Day 1 of each 14- or 21-day cycle as specified in the P-trial and as per clinical judgment and discretion of the investigator. The actual dose of onartuzumab will be determined on the bases of participants weight at the time of enrollment in extension trial (E-trial).

DRUG

Bevacizumab

All participants will continue on the same dose and schedule of control treatment (bevacizumab) as specified in their respective P-trial.

DRUG

Erlotinib

All participants will continue on the same dose and schedule of control treatment (erlotinib) as specified in their respective P-trial.

Trial Locations (10)

2193

University of the Witwatersrand Research, Johannesburg

2196

Sandton Oncology Medical Group, Sandton

10126

Azienda Ospedaliero Universitaria San Giovanni Battista Di Torino, Turin

28050

HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia, Madrid

34000

Clin Hospital Center - Kragujevac; Pulmonary Diseases, Kragujevac

59037

Hopital Roger Salengro, Lille

153040

Ivanovo Regional Oncology Dispensary, Ivanovo

791-0280

National Hospital Organization Shikoku Cancer Center, Ehime

LV 1079

Rigas Austrumu Kliniska Universitates slimnica, Latvijas Onkologijas centrs, Riga

08035

Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY